Abstract:Background: The role of locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma (mNPC) patients is unclear.Methods: mNPC patients with biopsy-proven disease, who demonstrated complete or partial response (RECIST v1.1) following 3 cycles of cisplatin and 5-fluorouracil chemotherapy, were enrolled. Eligible patients were randomly assigned (1:1) to receive either chemotherapy plus radiotherapy or chemotherapy alone. The chemotherapy regimens were 5-fluorouracil continuous intravenous infusion at 5 gm/m2 over 120 h and 100 mg/m2 intravenous cisplatin on day 1, administered every 3 weeks for six cycles. Patients assigned to the chemotherapy plus radiotherapy group received intensity-modulated radiotherapy (IMRT) after chemotherapy. Primary endpoint of the study was overall survival (OS).Findings: 126 of 173 patients screened were eligible to the study, and randomized to chemotherapy plus radiotherapy (n = 63) or chemotherapy alone (n = 63). Median follow-up duration was 26.7 months (IQR 17.2-33.5). The study met its primary end-point of improved OS (stratified hazard ratio [HR] = 0.42; 95% confidence interval [CI], 0.23-0.77; P = 0.004) in favor of chemotherapy plus radiotherapy. PFS was also improved in the chemotherapy plus radiotherapy group compared to the chemotherapy alone group (stratified HR = 0.36; 95% CI 0.23-0.57). No significant differences in acute hematological or gastrointestinal toxicities were observed between the treatment arms. The frequency of acute ≥grade 3 dermatitis, mucositis, and xerostomia was 8.1%, 33.9%, and 6.5%, respectively, in the chemotherapy plus radiotherapy group. The frequency of late severe ≥grade 3 hearing loss and trismus was 5.2% and 3.4%, respectively, in the chemotherapy plus radiotherapy group.Interpretation: Radiotherapy added to chemotherapy significantly improved OS in chemotherapy-sensitive mNPC patients.Trial Registration: This trial was registered as NCT02111460.Funding Statement: Funding was provided by the Program of Sun Yat-Sen University for Clinical Research 5010 Program (No.201310), the National Natural Science Foundation of China (No.81572912, 81772895, 81874134), Guangdong Province Science and Technology Development Special Funds (Frontier and Key Technology Innovation Direction – Major Science and Technology Project) (No. 703040078088), Guangzhou Science and Technology Planning Project - Production and Research Collaborative Innovation Major Project (No. 201505012235268). MC is supported by the National Medical Research Council Singapore Clinician-Scientist Award - #NMRC/CSA/0027/2018 and the Duke-NUS Oncology Academic Program Proton Research Program. This research is also supported by the National Research Foundation Clinical Research Programme Grant (NRF-CRP17-2017-05).Declaration of Interests: The authors declare that they have no conflicts of interest.Ethics Approval Statement: The study protocol was approved by the ethics committee of the Sun Yat-sen University Cancer Center (SYSUCC). The trial was performed in accordance with the Declaration of Helsinki, and the results are reported according to the CONSORT statement. All participants provided written informed consent.

Multicenter, Randomized, Controlled, Open-Label Study of Bevacizumab Combined with Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel in Patients with Metastatic Nasopharyngeal Carcinoma.

First-line Paclitaxel Plus Carboplatin With/without Bevacizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Randomized, Open-Label, Phase II Trial

Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial

Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ill Study Of Anlotinib Or Placebo In Combination With Gemcitabine And Cisplatin (Gp) As First -Line Treatment For Recurrent Or Metastatic Nasopharyngeal Carcinoma (R/M Npc).

Efficacy and Safety of Camrelizumab and Apatinib Combined with Induction Chemotherapy and Concurrent Chemoradiotherapy for Stage T Any N3M0 Nasopharyngeal Carcinoma: A Phase II QUINTUPLED Trial.

Chemotherapy combined with anlotinib, toripalimab and stereotactic radiotherapy in oligo-metastatic nasopharyngeal carcinoma: A prospective, multicenter phase II clinical study.

Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: An open-label phase II study.

Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma Interim Results from 2 Prospective Phase 2 Clinical Trials

A randomized, multicenter phase III clinical trial comparing gemcitabine and cisplatin with 5-fluorouracil and cisplatin in the treatment of recurrent or metastatic nasopharyngeal carcinoma.

1108OChemotherapy plus local-regional radiotherapy versus chemotherapy alone in primary metastatic nasopharyngeal carcinoma: A randomized, open-label, phase III trial

Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel ( nab ®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma

Efficacy and Safety of Chemotherapy Plus Subsequent Locoregional Radiotherapy and Toripalimab in De Novo Metastatic Nasopharyngeal Carcinoma.

Preliminary Result of Phase I/II Clinical Trial of Docetaxel, Cisplatin, and Fluorouracil Regimen Induction Chemotherapy for Primary Locoregionally Advanced Nasopharyngeal Carcinoma

A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination with Carboplatin Plus Paclitaxel in Patients with Previously Untreated Advanced Mucosal Melanoma.

TIRA Study: A Phase III, Multicenter, Randomized Controlled Study of Toripalimab Plus Radical Chemoradiotherapy with or Without Concurrent Cisplatin in Patients with High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma.

Neoadjuvant Docetaxel-Cisplatin Followed by Concurrent Chemoradiotherapy and Adjuvant Tislelizumab for Locally Advanced Nasopharyngeal Carcinoma: A Multicenter, Single-Arm, Phase II Trial.

Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial

A Multicenter Randomized Controlled Phase 3 Trial of Locoregional Radiotherapy in Combination with Chemotherapy in De Novo Metastatic Nasopharyngeal Carcinoma

Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.

Prospective Study of Cetuximab with Cisplatin Plus Docetaxel Followed by Concurrent Radiotherapy Plus Cetuximab and Cisplatin in Patients with Chemotherapy-Naive Metastatic Nasopharyngeal Carcinoma